ARCHIVED EDITORIALS
Send Page To a Friend | Thursday July 24, 2008


Allon Therapeutics Remains On-Track to Capitalize on an Unmet Multi-Billion Dollar Market for Alzheimer’s Disease and other Brain Illnesses
By Marc Davis, Managing Editor
November, 2007

Corporate Overview
Allon Therapeutics Inc. (TSX: NPC) is a Vancouver-based biotech pioneer in the development of proprietary drugs that combat some of society’s most pervasive neurodegenerative conditions, including Alzheimer's disease.

Most significantly, the company’s two leading multi-application in-development drugs (known as compounds) exhibit “blockbuster drug” potential – representing a prospective multi-billion dollar combined marketplace.


read full article ...


Venture capital news
 
 
  © 2005 SmallCapMedia.com - All Rights Reserved.